IDH2 mutant inhibitor TQB3455

{
  "id": "MLC-T-ONC-014313",
  "term": "IDH2 mutant inhibitor TQB3455",
  "field": "Oncology and biomedicine",
  "definition": "An orally bioavailable inhibitor of mutated mitochondrial enzyme isocitrate dehydrogenase type 2 (IDH2; IDH-2), with potential antineoplastic activity. Upon oral administration, IDH2 mutant inhibitor TQB3455 specifically inhibits mutated IDH2, thereby inhibiting the formation of the oncometabolite 2-hydroxyglutarate (2HG) from alpha-ketoglutarate (a-KG). This prevents 2HG-mediated signaling and leads to both an induction of cellular differentiation and an inhibition of cellular proliferation in tumor cells expressing mutated IDH2. IDH2 is mutated in a variety of cancers, and mutated IDH2 initiate and drive cancer growth by catalyzing the formation of 2HG and blocking cell differentiation.",
  "synonyms": [
    "isocitrate dehydrogenase type 2 mutant inhibitor TQB3455"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/idh2-mutant-inhibitor-tqb3455/"
}